Photo credits
Why Olanzapine Still Matters
Olanzapine is one of the most effective antipsychotics ever brought to market, and one of the most metabolically toxic. Those two facts govern how you use it. The efficacy is hard to argue with: in the NIMH-funded CATIE trial it produced the longest time-to-discontinuation of any second-generation agent (roughly 9 months versus 3.5 to 6 months for its competitors), the best symptom scores, and the lowest rate of stopping for lack of effect. In a network meta-analysis of 402 trials and 32 oral antipsychotics, olanzapine sat with clozapine, amisulpride, zotepine and risperidone in the small group that reduced overall symptoms significantly more than most other agents. But it earned that CATIE win at a metabolic price: about 2 pounds of weight gain per month, plus rising glucose and lipids.
That leaves the drug in an uncomfortable place. It works when other agents have failed, it controls acute mania and agitation quickly and reliably, and it is cheap and generic. But over a year it will add 15 to 25 pounds to the average patient, quadruple the risk of new-onset diabetes relative to conventional agents, and drive triglycerides up by triple digits. Pretending that cost away is how patients end up diabetic.
Use olanzapine deliberately. Reserve it for indications strong enough to justify its liabilities, screen metabolic risk before you start, monitor weight, glucose, and lipids on a schedule you actually keep, and intervene early (metformin, lifestyle change, or a switch) when the numbers start to move.
Olanzapine is a high-efficacy drug with a high-cost side-effect profile. Prescribing it well means matching that profile to the right patient and managing the metabolic damage aggressively from day one.
Read olanzapine's reputation with one CATIE caveat in mind. Its superior showing was partly an artifact of dosing: the average olanzapine dose in CATIE, about 20 mg/day, sat at the ceiling of its approved range. Olanzapine is effective, but some of its trial dominance reflects being pushed harder than the drugs it was compared against. Keep that in mind when you weigh "it's the strongest atypical" against "it's the most metabolically dangerous."
Part 1: Indications
FDA-Approved Uses
- Schizophrenia: acute and maintenance treatment
- Bipolar I disorder, acute manic or mixed episodes: monotherapy or adjunct to lithium/valproate
- Bipolar I maintenance
- Bipolar depression: only in fixed combination with fluoxetine (Symbyax, olanzapine-fluoxetine combination, OFC)
- Treatment-resistant depression: the olanzapine-fluoxetine combination is approved for MDD that has failed adequate antidepressant trials
- Agitation associated with schizophrenia and bipolar mania: via the short-acting intramuscular formulation
The Evidence-Based Clinical Uses
Schizophrenia, the core indication. Here olanzapine's efficacy most readily justifies its metabolic cost. In CATIE, olanzapine had the longest retention and the best PANSS/CGI outcomes of the atypicals studied. Its effect size for schizophrenia (about 0.55) sits at the top of the first-line group, below only clozapine (about 0.9). For a patient with a robust psychotic illness who has done poorly on metabolically cleaner agents, olanzapine is a rational and often decisive choice.
Acute mania and acute agitation, olanzapine's practical sweet spot. Olanzapine is sedating, fast-acting, and reliably effective, and it excels at bringing down an acutely manic or agitated patient. The orally disintegrating tablet (Zydis) and the short-acting IM formulation are standard tools on inpatient units. In this brief window, the sedation and appetite effects that plague long-term use work in your favor.
Treatment-resistant depression (augmentation). Historically, olanzapine was the best-evidenced second-generation antipsychotic for TRD augmentation: a double-blind RCT showed olanzapine plus fluoxetine superior to either agent alone. In practice, aripiprazole and brexpiprazole have largely displaced it in this role because they carry a fraction of the metabolic burden. Olanzapine augmentation remains a reasonable option for TRD when metabolically lighter augmenters have failed.
Bipolar depression. Olanzapine monotherapy is only marginally better than placebo for the depressed pole (roughly 39% vs. 30% response). The fluoxetine combination performs much better (about 56% vs. 30% placebo), which is why the depression indication is for Symbyax, not olanzapine alone. In practice, quetiapine and lurasidone are preferred first-line for bipolar depression; the fluoxetine combination is rarely prescribed, in part because of the general caution around antidepressants in bipolar disorder.
Off-label uses with limited but credible support:
- Adjunctive treatment for refractory anxiety disorders, particularly treatment-resistant panic, added to an SSRI/TCA.
- PTSD: moderately effective for hyperarousal and sleep disturbance, since the sedation helps. Not first-line (SSRIs are); reserve for tough cases given cost and metabolic risk.
- Insomnia with mood/anxiety comorbidity: effective but a poor risk/benefit trade for simple insomnia; best reserved for the toughest cases given weight, glucose, and tardive dyskinesia risk.
- Chemotherapy-induced nausea and vomiting, and appetite stimulation (for example, in cachexia): the appetite and antiemetic effects that are liabilities in psychiatry are assets in oncology.
Where olanzapine underperforms:
- Borderline personality disorder: one large trial showed little to no benefit; aripiprazole did better.
- Clinical high-risk (prodromal) states: antipsychotics reduce symptom intensity but do not clearly prevent conversion to psychosis, and the metabolic risk in young, first-exposure patients is especially steep. Advised against as routine practice in adolescents.
The single most useful question before writing olanzapine is: "Is this indication robust enough to justify 15 to 25 pounds and a fourfold diabetes risk?" For acute mania, treatment-resistant schizophrenia, or a patient who has already failed cleaner agents, the answer is often yes. For first-line anxiety, insomnia, or a young patient with an ambiguous diagnosis, the answer is usually no: start with something metabolically cleaner (aripiprazole, lurasidone, ziprasidone) and hold olanzapine in reserve.
Part 2: Before You Start: Workup and Candidacy
Because olanzapine's chief danger is metabolic, the pre-start workup is, in practice, a metabolic-risk assessment.
Baseline Workup
| Assessment | Why |
|---|---|
| Weight and BMI (ideally waist circumference) | The number you'll track most closely; establish it before the drug moves it |
| Fasting glucose (or HbA1c) | Baseline for a drug that quadruples diabetes risk; normal fasting <100, pre-diabetes 100–125, diabetes ≥126 mg/dL |
| Fasting lipid panel | Total cholesterol, LDL, HDL, triglycerides; olanzapine raises triglycerides most dramatically |
| Blood pressure | Component of metabolic syndrome; baseline for orthostasis |
| Personal/family history of diabetes, dyslipidemia, obesity, HTN | A positive family history of diabetes roughly quadruples the risk, which reshapes the risk/benefit calculus |
| ECG | Only if cardiac history or other QTc risk: olanzapine is not a significant QTc drug and no routine ECG is required |
| hCG | In any woman of childbearing potential |
| CBC / LFTs | Reasonable general baseline; olanzapine is hepatically metabolized. Not a mandatory monitored parameter like clozapine's ANC |
Note what is not required: no mandatory prolactin monitoring (olanzapine is prolactin-sparing), no routine ECG, and nothing resembling clozapine's blood-count surveillance.
Who Is a Poor Candidate?
- Patients with existing type 2 diabetes, metabolic syndrome, or significant obesity: olanzapine will make all of it worse, and cleaner options exist.
- Young, first-episode, antipsychotic-naive patients, who are at the highest risk of rapid weight gain: weigh this heavily and consider a cleaner first agent.
- Adolescents, especially for prodromal or ambiguous presentations: metabolic vulnerability is greatest here.
- Elderly patients with dementia-related psychosis: this is an off-label use carrying a boxed warning for increased mortality (see Part 6), and real-world data show poor effectiveness with heavy side-effect burden in older adults.
None of these is an absolute bar, but each shifts you toward a metabolically cleaner agent unless you need olanzapine's efficacy edge.
Part 3: How to Start and Dose
Ages 13–17schizophrenia, bipolar I maniaFDA labelStart 2.5 or 5 mg; target 10 mg a day; efficacy shown 2.5–20 mg a day.In practiceStart low; the metabolic burden is even more concerning in youth.
Older adultsschizophreniaFDA labelStart 5 mg if debilitated, prone to hypotension, may be more pharmacodynamically sensitive, or with a combination of factors that may slow metabolism.In practiceStart at 5 mg or lower, then titrate slowly.
When to take itFDA labelOnce a day, without regard to meals. Steady state takes about 1 week.In practiceGenerally at bedtime; early sedation usually fades in 1–2 weeks.
StoppingFDA labelNo labeled dose for stopping.In practiceA common approach: cut by 25–50%, then halve again, over weeks to months. Do not stop abruptly.
Acute agitation (IM)schizophrenia, bipolar I maniaFDA label10 mg per injection; up to 10 mg more may be given if agitation persists; daily totals above 30 mg not evaluated.In practice10 mg, may repeat; no more than 30 mg a day. Do not combine with a parenteral benzodiazepine.
Formulations
- Standard oral tablets: the default.
- Orally disintegrating tablet (Zyprexa Zydis): same dosing as tablets; detectable in serum by about 10 minutes (vs. about 30 for standard tablets). It dissolves instantly and is nearly impossible to "cheek," which makes it valuable for acute agitation and for patients you worry aren't swallowing their meds. The early hope that rapid sublingual absorption would reduce weight gain was debunked: three RCTs found no metabolic advantage over standard tablets.
- Short-acting IM: for acute agitation.
- Long-acting injectable (Zyprexa Relprevv): no oral loading needed (unlike Risperdal Consta). It does carry a distinctive hazard, post-injection delirium/sedation syndrome (see Part 6). It requires at least 3 hours of post-injection observation and enrollment in a monitoring program, and is therefore typically initiated by specialists.
Starting Dose and Titration
- Start: 10 mg once daily, generally at bedtime (QHS): the half-life of 21 to 54 hours (mean about 30 hours) supports once-daily dosing, and nighttime dosing turns the early sedation into a sleep aid.
- Lower start (5 mg) in the elderly, the medically frail, or the metabolically vulnerable.
- Typical target: 15 to 20 mg/day. Olanzapine's effective dose runs higher than many competitors.
- Do not go above 20 mg/day: the label does not indicate olanzapine above that, and extrapyramidal symptoms already climb with dose inside the approved range.
- Minimum effective maintenance dose: ≥5 mg/day (below this, efficacy is unreliable).
- Titration is straightforward: there is no narrow therapeutic window to respect and no serum level to chase. Move by 5 mg every several days as tolerated and as symptoms demand. In acute mania or agitation, you can reach a therapeutic dose quickly.
The Dose-Reduction Principle for Maintenance
Stable patients can often be maintained on substantially lower doses than they needed acutely, one of the most useful and underused facts about olanzapine (and antipsychotics generally). In a 52-week trial in stabilized schizophrenia, cutting the dose by 50% did not increase relapse (4 vs. 6 relapses) and produced measurably fewer EPS, lower BMI, better cognition, and better negative symptoms. Once a patient is stable, actively test whether you can come down: the metabolic and cognitive dividends are real.
There is no lab level to titrate to and no toxic window to fear on the pharmacokinetic side, and that ease invites complacency. The discipline olanzapine demands is weighing the patient, checking glucose and lipids on schedule, and being willing to lower the dose or switch when the metabolic numbers move.
Dose Adjustments and Special Populations
- Long-acting injectable: Zyprexa Relprevv can cause post-injection delirium/sedation syndrome (PDSS); it requires REMS enrollment and at least 3 hours of post-injection observation, and is specialist-initiated.
- Renal impairment: no dose adjustment. Hepatic impairment: no routine adjustment, but dose cautiously and consider a lower start in significant liver disease. Geriatric: start 5 mg; class boxed warning applies.
Stopping and Switching
- Discontinuation: taper to reduce cholinergic/rebound symptoms; in stable maintenance, actively test a dose reduction, which pays off metabolically and cognitively.
Part 4: Monitoring
Olanzapine is a "metabolically dirty" antipsychotic, and its monitoring is metabolic monitoring. There is no required blood level, no mandatory ECG, and no ANC surveillance, but the metabolic labs are not optional.
Metabolic Monitoring Schedule
| Parameter | Schedule |
|---|---|
| Weight / BMI | Baseline → monthly for the first 3 months → every 3 months thereafter |
| Fasting glucose (or HbA1c) | Baseline → ~3–4 months after starting → then yearly (keep it every ~4 months if weight is still climbing) |
| Fasting lipid panel | Baseline → 3 months → then periodically (roughly every 1–2 years if stable; sooner if abnormal). Refer to PCP if LDL >130 mg/dL |
| Blood pressure | At visits, as part of metabolic-syndrome surveillance |
Monitor more frequently in the highest-risk groups: young patients, first-time antipsychotic users, and anyone with baseline metabolic risk factors. Screen clinically for polyuria and polydipsia: these can be the first signs of emerging hyperglycemia.
What Is NOT Routinely Required
- Prolactin: screen by symptom only (menstrual changes, galactorrhea, libido/sexual dysfunction); olanzapine rarely elevates prolactin meaningfully.
- ECG: only for cardiac history; olanzapine is not a QTc concern.
- Serum drug levels: not clinically useful for olanzapine.
The Specific Thresholds to Act On
- Weight gain ≥5–7% of baseline (or ~1 lb/week trending): intervene now, with lifestyle counseling, added metformin, or a planned switch. Don't wait for frank obesity.
- Fasting glucose ≥100 (pre-diabetes) or ≥126 (diabetes), or a rising HbA1c: engage the metabolic problem directly, with metformin, PCP referral, and reconsideration of the agent.
- Triglycerides or LDL rising (LDL >130): lifestyle, statin referral, reconsider agent.
Diabetes on olanzapine typically emerges within the first 6 months, and lipid changes manifest within the first year, so the early checks matter most.
The metabolic damage is front-loaded. Weight gain is fastest in the first 10 weeks (about 1 lb/week), diabetes usually declares itself within 6 months, and lipids move within the first year. Front-load your monitoring to match: the first three months are when you catch, and can still prevent, most of the trouble.
Part 5: Side Effects and How to Manage Them
Olanzapine's efficacy is not in doubt; its tolerability is. The metabolic side effects are the ones that harm patients and drive discontinuation, and they must be managed proactively from initiation rather than after the weight is on.
The Metabolic Triad: Weight, Glucose, Lipids
These three dominate the drug's story.
Weight gain. The landmark Allison meta-analysis and CATIE agree: about 1 pound per week for the first 10 weeks, then the slope tapers; average 1-year gain of 15 to 25 pounds (CATIE: about 2 lb/month). Roughly half of patients gain ≥10% of body weight. Olanzapine causes more weight gain than valproate, risperidone, quetiapine, or ziprasidone in head-to-head comparisons; its weight liability rivals clozapine's. Highest-risk: younger patients and first-time antipsychotic users.
Glucose and diabetes. Olanzapine confers roughly a 4-fold increased risk of new-onset type 2 diabetes vs. conventional agents (UK GP database, about 20,000 patients), compared to a non-significant ~1.6-fold for risperidone. The absolute incidence in controlled data is modest (on the order of about 1%), and many cases are diet-and-exercise manageable, but case series document severe presentations, including diabetic ketoacidosis and deaths from complications. Onset is usually within 6 months.
Lipids. Olanzapine raises lipids more than most agents: a ~4.7-fold increased risk of hyperlipidemia vs. no antipsychotic and ~3-fold vs. conventional agents. In a head-to-head chart review, one year of olanzapine raised triglycerides by about +105 mg/dL and total cholesterol by about +31 mg/dL, versus about +32 and +7 for risperidone. Risperidone, by contrast, shows no significant increase in hyperlipidemia risk.
Management, proactive and stepped
- Set expectations and start lifestyle counseling on day one. Diet, exercise, sleep hygiene, smoking cessation. Educating patients about the weight risk increases their reporting of it but decreases discontinuation, so be candid up front.
- Choose the right patient in the first place. If metabolic risk is high and the indication permits, a cleaner agent (aripiprazole, ziprasidone, lurasidone) avoids the problem entirely.
- Metformin, the first-line pharmacologic adjunct when weight is climbing. Dose 500 mg BID, titrated toward 1,500 to 2,000 mg/day (meta-analytic range 750 to 2,500 mg/day). Yields about 7 lb of weight loss vs. placebo and also improves insulin resistance and triglycerides. Onset takes about 3 months. Main side effects are GI (nausea, diarrhea); avoid if eGFR <30 or in metabolic acidosis. Metformin does more for the whole metabolic picture than any other option.
- Topiramate: comparable weight effect (about 6.8 lb vs. placebo at about 200 mg/day, range 50 to 400) with a bonus signal on positive/negative symptoms. Costs: cognitive dulling, paresthesias, renal stones.
- Olanzapine-samidorphan (Lybalvi): olanzapine bundled with an opioid antagonist; yields about 5 lb less gain than olanzapine alone at 6 months. But it does nothing for glucose or lipids, was only tested in non-obese patients (BMI about 26), costs about $1,300/month, and is contraindicated in patients on opioids. Second-line at best; metformin is preferred for its broader metabolic benefit.
- GLP-1 receptor agonists (for example, liraglutide, and by extension semaglutide): strong and growing evidence for antipsychotic-associated weight gain; second-line when metformin/topiramate are insufficient. Subcutaneous; also improve glucose, BP, and lipids.
- Older adjuncts with some evidence: the H2-blocker nizatidine (Axid) 300 mg BID and amantadine 100 mg BID. Most clinicians reasonably avoid adding a second drug on day one purely prophylactically.
- When metabolic parameters can't be controlled, switch. Cross-taper to a low-metabolic-risk agent (aripiprazole, brexpiprazole, lumateperone, lurasidone, ziprasidone).
Olanzapine's metabolic damage is easiest to prevent before it starts, by choosing the right patient, and next easiest at the first appointment, with candid counseling and a low threshold to add metformin. Once someone has gained 40 pounds and become diabetic, you're managing a chronic disease you helped create.
Sedation
Common early (histamine H1 blockade), usually mild-to-moderate and waning over 1 to 2 weeks. Manage with QHS dosing, which converts it into a sleep benefit. In agitation or insomnia this is the desired effect.
Extrapyramidal Symptoms (EPS)
Modest at low doses and dose related across the approved range: in the fixed-dose registration trial, spontaneously reported extrapyramidal events occurred in 15% of patients on 5 ± 2.5 mg/day, 25% on 10 ± 2.5 mg/day and 32% on 15 ± 2.5 mg/day, against 16% on placebo. In CATIE, atypicals including olanzapine did not produce significantly more movement effects than the conventional comparator (perphenazine). Manage emergent EPS by lowering the dose (often sufficient), an anticholinergic (benztropine 0.5 to 2 mg BID) for parkinsonism/dystonia, and for akathisia, propranolol 20 to 40 mg BID (anticholinergics do not treat akathisia).
Tardive Dyskinesia
Annualized incidence is about 2.6–3.9% with second-generation antipsychotics against 5.5–6.5% with first-generation ones (Carbon 2018, head-to-head trials; Correll and Schenk 2008, all ages). Screen periodically (AIMS) with long-term use; risk rises with age, dose, and duration. A VMAT2 inhibitor (valbenazine, deutetrabenazine) is the treatment if TD develops.
Anticholinergic Effects
Olanzapine has moderate anticholinergic activity: expect some dry mouth, constipation, and, in the vulnerable, urinary hesitancy or cognitive fog. Manage dry mouth with sugar-free gum and water; constipation with a routine bowel regimen (fiber, stool softener); watch the elderly for anticholinergic delirium.
Cognitive Effects
Antipsychotics can slow processing speed at higher doses, though verbal/working memory often improves with treatment of psychosis. In older patients, olanzapine has been associated with measurable MMSE decline. This is another argument for the lowest effective maintenance dose: the 50%-reduction data showed cognition improved when the dose came down.
Prolactin
Minimal: unlike risperidone/paliperidone, olanzapine does not meaningfully elevate prolactin. Screen by symptom only.
Cardiac / QTc
Not a primary concern. Olanzapine is not a significant QTc-prolonging agent, and no routine ECG is required.
Part 6: Overdose, Toxicity, and Boxed Warning
Like all antipsychotics, olanzapine carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis (relative risk approximately 1.6 to 1.7; deaths largely cardiovascular and pneumonia-related; cerebrovascular events also increased). Olanzapine is not approved for dementia-related psychosis. If you can't avoid an antipsychotic in this population, use the lowest effective dose for the shortest necessary time with informed consent, and real-world data in older adults show poor effectiveness with heavy side-effect burden, so the bar should be high.
Neuroleptic Malignant Syndrome (NMS)
Rare but life-threatening: fever, rigidity, altered mental status, autonomic instability (labile BP, tachycardia, diaphoresis), with elevated CK. Stop the antipsychotic immediately; provide aggressive supportive care and cooling; dantrolene and/or bromocriptine for severe cases. NMS is a medical emergency.
Post-Injection Delirium/Sedation Syndrome (Zyprexa Relprevv LAI Only)
Unique to the long-acting injectable, and the subject of a separate boxed warning specific to the Relprevv formulation. With inadvertent intravascular delivery, a rapid spike in olanzapine produces delirium and/or profound sedation, with slurred speech, confusion, tremor, and somnolence. Most events begin within the first 3 hours, and some have begun later. In premarketing studies these events occurred in under 0.1% of injections and in about 2% of patients. That risk is why Relprevv requires at least 3 hours of post-injection observation and enrollment in a monitoring program.
Metabolic Emergencies
Olanzapine can precipitate diabetic ketoacidosis and severe hyperglycemia, sometimes as the presenting event of new diabetes. Counsel patients to report polyuria, polydipsia, and rapid unexplained symptoms; these are ED evaluations.
Acute Overdose
There is no specific antidote. Management is supportive: airway protection, cardiac and vital-sign monitoring, and symptomatic treatment. Anticipate profound sedation, anticholinergic effects (tachycardia, delirium), and orthostatic hypotension. Olanzapine overdose is far more often disabling (deep sedation, confusion) than lethal when supportive care is prompt.
Part 7: Drug Interactions
Olanzapine is metabolized primarily by CYP1A2, with a secondary contribution from CYP2D6. Most of its clinically important interactions run through 1A2.
Smoking (CYP1A2 Induction)
Smoking is olanzapine's most important interaction. Tobacco smoke induces CYP1A2 and lowers olanzapine levels, so smokers need higher doses. The polycyclic aromatic hydrocarbons in smoke, not the nicotine, drive this, so nicotine replacement does not induce.
When a smoker on stable olanzapine quits, classically during a psychiatric or medical hospitalization where they can't smoke, their olanzapine levels rise and they can become oversedated or worse. Anticipate a dose reduction when a patient stops smoking, and an increase if they resume.
Drugs That Raise Olanzapine Levels
- Fluvoxamine: a potent CYP1A2 inhibitor that can substantially increase olanzapine levels; use the combination cautiously and consider a lower olanzapine dose.
- Ciprofloxacin and other 1A2 inhibitors: monitor for increased effect/sedation.
- CYP2D6 inhibitors: a minor pathway for olanzapine. Fluoxetine raises olanzapine peak concentration by about 16% and lowers clearance by about 16%, small against the variability between patients, so routine dose modification is not recommended.
Drugs That Lower Olanzapine Levels
- Smoking (above).
- Carbamazepine: a broad inducer that lowers nearly all antipsychotic levels, olanzapine included; expect to dose higher if co-prescribed.
Pharmacodynamic Interactions
- CNS depressants (alcohol, opioids, benzodiazepines, antihistamines): additive sedation and, with respiratory depressants, additive respiratory risk. Parenteral olanzapine plus a parenteral benzodiazepine is not recommended, because of the potential for excessive sedation and cardiorespiratory depression.
- Anticholinergics: additive anticholinergic burden (constipation, urinary retention, confusion).
- Antihypertensives: additive orthostatic hypotension.
Olanzapine has no major pharmacokinetic interaction with lithium or valproate and is routinely combined with them in bipolar disorder (watch additive sedation and weight).
Part 8: Special Populations
Pregnancy
The data are reasonably reassuring by antipsychotic standards. The Toronto Motherisk cohort (151 women on atypicals, 60 on olanzapine) found major malformations in 0.9% of exposed vs. 1.5% of unexposed (no signal of increased teratogenicity) and no difference in prematurity, birth weight, or obstetric complications. Larger datasets are broadly consistent, and olanzapine is generally considered one of the better-studied atypicals in pregnancy.
Two practical cautions:
- Olanzapine's metabolic effects compound the metabolic stress of pregnancy: watch weight and screen for gestational diabetes (higher birth weight has been noted with in-utero exposure).
- As always, weigh the real risks of untreated maternal illness (relapse, disorganization, poor self-care) against medication risk; for many women with serious psychosis or bipolar illness, continuing an effective antipsychotic is the safer course. Manage with a multidisciplinary team (OB, psychiatry, patient/partner). Neonates exposed in the third trimester should be watched for transient EPS/withdrawal signs.
Breastfeeding
Olanzapine is excreted into breast milk in small amounts and is generally considered compatible with breastfeeding among the atypicals. Monitor the infant for sedation and poor feeding. Coordinate with pediatrics.
Elderly
- Start low (5 mg or lower), titrate slowly, and expect greater sensitivity to sedation, orthostasis, anticholinergic effects, and parkinsonism.
- Respect the boxed warning in dementia-related psychosis. Real-world 2-year data in older adults (mean age about 67) found no improvement in psychosis measures, adverse events in over half, metabolic syndrome in about 36%, and early discontinuation, a sobering picture. Use the lowest dose for the shortest time, and consider that quetiapine or aripiprazole may be better tolerated in this group.
Renal Impairment
Olanzapine is hepatically, not renally, cleared: routine dosing is generally acceptable in renal impairment, and no specific renal dose adjustment is standard. Note that if you're adding metformin for weight, that drug is renally limited, so avoid metformin if eGFR <30.
Hepatic Impairment
Olanzapine is hepatically metabolized; in significant liver disease, dose cautiously and monitor (including LFTs if symptomatic). It is not contraindicated, but the frail hepatic patient warrants a lower, slower approach.
Children and Adolescents
FDA-approved down to age 13 for schizophrenia and bipolar mania, but used cautiously. Youth are at the highest metabolic risk (faster, larger weight gain and glucose/lipid changes than adults), so olanzapine is generally not a first choice in this group, and it is specifically advised against for prodromal/high-risk states except in severe, rapidly worsening cases. Monitor weight, glucose, and lipids closely when it is used.
Part 9: Discontinuation and Taper
Olanzapine has no dramatic dependence syndrome, but it should not be stopped abruptly in established patients. Two distinct risks apply.
Psychotic/mood relapse. Relapse risk is highest in the first 1 to 6 months after stopping, and maintenance meaningfully reduces it: patients are roughly twice as likely to stay well on continued treatment (in the bipolar maintenance literature, 6-month relapse about 32% on maintenance vs. about 53% off).
Dopamine supersensitivity and withdrawal phenomena. Chronic D2 blockade upregulates D2 receptors; abrupt withdrawal can unmask rebound psychosis (sometimes worse than the original episode) and, less commonly, a withdrawal-emergent dyskinesia (choreiform movements peaking 1 to 4 weeks after stopping). There can also be cholinergic-rebound effects (nausea, insomnia, agitation) from removing the anticholinergic load quickly.
How to Stop
- Taper gradually: a common approach is to reduce by 25 to 50%, then halve again, over weeks to months rather than days. For long-term, stable patients, a slow taper (on the order of months, sometimes up to a year) is prudent; brief courses can be tapered faster.
- Watch most closely near the bottom of the taper, where breakthrough symptoms tend to appear.
- If a withdrawal dyskinesia or rebound psychosis emerges, reinstate the prior dose and taper more slowly.
- Not every patient needs lifelong treatment (a single brief reactive psychosis may warrant a trial off medication), but the decision to stop should be deliberate, gradual, and monitored, with a plan to resume promptly if symptoms return.
Part 10: Olanzapine vs the Alternatives
Across the comparisons, olanzapine wins on efficacy and loses on metabolism.
| Comparison | Olanzapine Advantage | Alternative Advantage |
|---|---|---|
| vs Risperidone | Comparable efficacy; no significant prolactin elevation | No significant hyperlipidemia; far less weight/metabolic derangement (triglyceride and cholesterol rises 3–4x smaller; ~1.6x vs ~4x diabetes risk) |
| vs Quetiapine | Similar efficacy; less sedating | Preferred for bipolar depression and EPS-prone or elderly patients (lowest EPS); overall less metabolically damaging |
| vs Ziprasidone / Aripiprazole | More sedating: beats these decisively for acute agitation efficacy | Minimal weight, glucose, and lipid effects ("metabolically clean"); ziprasidone carries a modest QTc signal and needs food for absorption; aripiprazole has the best metabolic profile and lowest sedation |
| vs Lurasidone | More sedating and more effective acutely | Metabolically clean; strong for bipolar depression; requires food and can cause akathisia |
| vs Clozapine | No ANC monitoring, no agranulocytosis/myocarditis/seizure/ileus/sialorrhea risk | More effective for treatment-resistant schizophrenia; uniquely reduces suicide. Metabolically the two are comparable |
Olanzapine is, in effect, "most of clozapine's efficacy without the agranulocytosis," which is why many prescribers reach for it when they want maximal efficacy short of clozapine.
Where olanzapine belongs in the algorithm: as a high-efficacy option for strong indications: acute mania and agitation, schizophrenia (especially after cleaner agents underperform), and treatment-resistant depression augmentation when lighter augmenters have failed. It is generally not the right first-line choice for young/first-episode patients, metabolically vulnerable patients, or soft indications (anxiety, insomnia, prodrome), where a cleaner agent should lead.
Assume the first-line atypicals are roughly equally effective and differentiate by side-effect liability. Metabolic risk or diabetes: avoid olanzapine, prefer aripiprazole/ziprasidone/lurasidone. Need maximal efficacy or fast control of mania/agitation: olanzapine earns its place. EPS-prone or elderly: quetiapine. Prolactin/sexual side effects a concern: olanzapine is actually favorable (prolactin-sparing).
Mechanism
Olanzapine is a multi-receptor antagonist. Its antipsychotic action comes from combined D2 dopamine and 5-HT2A serotonin blockade: D2 antagonism in mesolimbic pathways quells positive symptoms, while 5-HT2A antagonism in nigrostriatal regions preserves enough dopamine tone to keep EPS low. That trade defines the second-generation class, and it is the reason olanzapine's movement-disorder risk is modest at usual doses.
The rest of the receptor map accounts for the side effects. Potent histamine H1 blockade drives sedation and, together with effects on hypothalamic appetite regulation (including 5-HT2C antagonism) and downstream metabolic pathways, the prodigious appetite and weight gain. Muscarinic (anticholinergic) blockade yields dry mouth, constipation, and cognitive fog. Alpha-1 adrenergic blockade contributes orthostasis. The glucose and lipid derangement is not fully explained by weight alone: olanzapine appears to have direct effects on insulin sensitivity and lipid metabolism. That is why glucose and triglycerides can worsen even before dramatic weight gain, and why watching the scale can't replace metabolic monitoring.
Pharmacokinetically: half-life 21 to 54 hours, mean about 30 hours (once-daily dosing), steady state about 1 week, hepatic metabolism via CYP1A2 (major) and CYP2D6.
Bedside Cheat Sheet
Starting
- Generic olanzapine, 10 mg QHS (5 mg in elderly/frail/metabolically vulnerable); label target in schizophrenia 10 mg/day (15–20 mg/day only after clinical assessment)
- Doses above 20 mg/day are not indicated by the label (safety not evaluated in bipolar mania). EPS climbs with dose. Minimum effective ~5 mg
- Half-life 21–54 h (mean ~30 h); steady state ~1 week; no serum level to chase
- Baseline: weight/BMI, fasting glucose (or HbA1c), fasting lipids, BP, family metabolic history; hCG in women; ECG only if cardiac history
Monitoring (it's all metabolic)
- Weight: baseline → monthly ×3 → q3 months
- Glucose: baseline → ~3–4 months → yearly (q4 months if still gaining)
- Lipids: baseline → 3 months → periodically. LDL >130 → refer
- No routine prolactin, ECG, or drug levels
Side effects
- Metabolic triad dominates: ~1 lb/week ×10 weeks, 15–25 lb/year; ~4x diabetes, ~4.7x hyperlipidemia (TGs ~+105 mg/dL/year). Intervene at ≥5–7% weight gain
- First-line adjunct: metformin 500 mg BID → 1,500–2,000 mg/day (also improves insulin resistance and lipids). Alternatives: topiramate; GLP-1 agonists; Lybalvi (weight only, pricey). Or switch to a clean agent
- Sedation: usually fades in 1–2 weeks; dose QHS. EPS: dose related, modest at low doses. Anticholinergic: dry mouth/constipation. Prolactin: minimal
Don't forget
- Smokers who quit → olanzapine levels RISE (CYP1A2). Fluvoxamine raises levels; carbamazepine/smoking lower them
- Boxed warning: increased mortality in elderly dementia psychosis, not approved, high bar
- NMS = fever + rigidity + altered mental status + autonomic instability → stop drug, ED
- Relprevv LAI: post-injection delirium (<0.1%/injection, ~2% of patients) → at least 3 hours of observation
- Don't stop abruptly: taper over weeks-to-months; abrupt stop risks rebound psychosis and withdrawal dyskinesia
- Test lower maintenance doses: 50% reduction preserved efficacy while improving BMI, cognition, and EPS
Reach for olanzapine when you need efficacy and can afford to pay for it metabolically. It settles acute mania, controls agitation, and holds up against robust psychosis as well as anything short of clozapine, without clozapine's blood draws. That efficacy is real and worth having for the right patient. But the metabolic bill is just as real: weight, glucose, and lipids all move against your patient, fastest in the first weeks and months, and often for the rest of their life. Prescribed with discipline (the right indication, honest counseling, a monitoring schedule you keep, metformin at the first sign of trouble, and a willingness to lower the dose or switch), olanzapine remains one of the most powerful tools in psychiatry. Prescribed casually, it is one of the surest ways to make a psychiatric patient diabetic.